Concepedia

Author

Diana Cirstea

Dana-Farber Cancer InstituteORCID

Also Known As

D Cirstea, D D Cirstea, D. Cirstea, D. Cirstéa, Diana Cirstea, Diana D Cirstea, Diana D. Cirstea, Diana D. Cirstea

188

Publications

4.3K

Citations

29

H-Index

34

Concepts

All Affiliations

Dana-Farber Cancer InstituteHarvard UniversityMassachusetts General HospitalBrigham and Women's HospitalVA Boston Healthcare System
DC

About

Diana Cirstea is an author at Dana-Farber Cancer Institute specializing in medicine, cell biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

15

1.1K

2

Cell Biology

10

10

923

3

Public Health

1

1

12

4

Blood Transplantation

1

1

19

5

Epidemiology

1

1

12

Diana Cirstea

×

36

Publications

4K

Citations

27

H-Index

YearCitations

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung,

Blood

2012

594

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Naoya Mimura, Mariateresa Fulciniti, Güllü Görgün,

Blood

2012

431

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Güllü Görgün, Elisabetta Calabrese, Teru Hideshima,

Blood

2010

271

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Sonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela,

Proceedings of the National Academy of Sciences

2010

232

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Güllü Görgün, Elisabetta Calabrese, Ender Soydan,

Blood

2010

228

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>

Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti,

Clinical Cancer Research

2009

204

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>Nanoparticle Albumin-Bound</i> –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

Diana Cirstea, Teru Hideshima, Scott J. Rodig,

Molecular Cancer Therapeutics

2010

163

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

J. Minami, Rikio Suzuki, Ralph Mazitschek,

Leukemia

2013

158

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

Sonia Vallet, Samantha Pozzi, Kishan Patel,

Leukemia

2011

151

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Sonia Vallet, Noopur Raje, Kenji Ishitsuka,

Blood

2007

150

Page 1